DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN

27-Sep-2010 - USA

DBV Technologies (DBV) announced that its unique VIASKIN® delivery system has been granted two US patents. In both cases, the lifetime of the patent has been extended until 2026. Aspects of both patents (US 7,635,488 and US 7,722,897) are incorporated into DBV Technologies’ VIASKIN which delivers allergens compounds to the immune system though intact skin.

DBV Technologies’ VIASKIN is the first device especially developed for EPicutaneous ImmunoTherapy (EPIT). VIASKIN enhances hydration of the surface of the skin and allows the diffusion of allergens into the superficial layers, so that they can interact with the skin’s immune network in order to desensitize food allergy patients safely without any risk of systemic reactions. VIASKIN is applied on intact skin and is completely non-invasive.

Commenting on the announcement, DBV Technologies’ CEO and Co-Founder, Pierre-Henri Benhamou, MD said: “We are delighted to have secured two patents central to our VIASKIN technology, which further strengthen the competitiveness of our core technology and we are delighted this protection has been granted for an extended period. To date VIASKIN is successfully marketed as a diagnostic product but has also shown huge promise as a safe, painless and effective therapy for food allergy desensitization.”

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance